Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: the MULTIMOGAD study


Por: Marignier, R, Villacieros-alvarez, J, Espejo, C, Arrambide, G, Fissolo, N, Gutiérrez, L, Dinoto, A, Mulero, P, Rubio-Flores, L, Nieto, P, Alcalá, C, Meca-Lallana, JE, Martínez-Garcia, P, Millán, J, Bernard-Valnet, R, González, I, García, AO, Tellez, R, Navarro, L, Presas-Rodríguez, S, Romero-Pinel, L, Martínez-Yélamos, S, Cuello, JP, Torres, AMA, Piñar, R, Bravo, GA, Benyahya, L, Trouillet-Assant, S, Dyon-Tafani, V, Tilikete, CF, Ruet, A, Bourre, B, Deschamps, R, Papeix, C, Maillart, E, Kerschen, P, Ayrignac, X, Rovira, A, Auger, C, Audoin, B, Montalban, X, Tintore, M, Mariotto, S and Cobo-Calvo, A

Publicada: 1 sep 2025 Ahead of Print: 1 feb 2025
Resumen:
Background Serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) have emerged as important biomarkers in multiple sclerosis (MS) and aquaporin-4 seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD). However, their interest in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) remains unclear. Our aim was to characterise sNfL and sGFAP profile and analyse their usefulness in predicting relapses and disability in MOGAD. Methods Retrospective study of adult MOGAD patients with serum samples collected at baseline (<= 3 months from disease onset) and follow-up (>6 months from baseline sample). sNfL and sGFAP were analysed using Simoa HD-1, and values were compared across time-points. The association between biomarkers and clinical variables and their predictive value for disability and relapses were analysed. Results Eighty-nine MOGAD patients were included. Baseline sNfL and sGFAP values were high at baseline and decreased over time (p<0.001, p=0.027, respectively). sNfL and sGFAP values were associated with Expanded Disability Status Scale (EDSS) at attacks (beta 0.15 (0.06; 0.25), p=0.002; beta 0.14 (0.07; 0.21), p<0.001, respectively) and were lower in optic neuritis presentations (beta -0.69 (-1.18; -0.19), p=0.007; beta -0.42 (-0.76; -0.08), p=0.016). Biomarker deltas[Delta] (baseline values - second samples values) were associated with Delta EDSS (initial EDSS - final EDSS) (Delta sNfL beta 0.52 (0.01; 1.04), p=0.046; Delta sGFAP beta 1.07 (0.38; 1.75), p=0.003). Finally, sNfL values independently predicted the risk of relapses (HR 2.06 (1.41; 3.01), p<0.001). Conclusions Our results on sNfL and sGFAP suggest initial neuro-axonal and astrocytic damage in MOGAD and the utility of these biomarkers at onset and follow-up in predicting clinical recovery and relapses.

Filiaciones:
Marignier, R:
 Hosp Civils Lyon, Hop Neurol Pierre Wertheimer, Serv Neurol, Sclerose Plaques Pathol Myeline & Neuroinflammat, Lyon, France

Villacieros-alvarez, J:
 Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain

 Univ Autonoma Barcelona, Barcelona, Catalunya, Spain

Espejo, C:
 Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain

 Univ Autonoma Barcelona, Barcelona, Catalunya, Spain

Arrambide, G:
 Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain

 Univ Autonoma Barcelona, Barcelona, Catalunya, Spain

Fissolo, N:
 Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain

 Univ Autonoma Barcelona, Barcelona, Catalunya, Spain

Gutiérrez, L:
 Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain

 Univ Autonoma Barcelona, Barcelona, Catalunya, Spain

Dinoto, A:
 Hosp Clin Univ Valladolid, Serv Neurol, Valladolid, Spain

Mulero, P:
 Aravaca & Arturo Soria Univ Hosp, Vithas La Milagrosa, Synaptia Madrid Neurosci, Madrid, Spain

Rubio-Flores, L:
 Hosp Univ Rey Juan Carlos, Serv Neurocirugia, Madrid, Spain

 Hosp Univ & Politecn La Fe, Unidad Neuroinmunol, Valencia, Spain

Nieto, P:
 Hosp Univ & Politecn La Fe, Unidad Neuroinmunol, Valencia, Spain

Alcalá, C:
 Virgen La Arrixaca Clin Univ Hosp, Neurol Dept, Multiple Sclerosis CSUR, Clin Neuroimmunol Unit,IMIB Arrixaca, Murcia, Spain

 UCAM San Antonio Catholic Univ, NICEM Cathedra, Murcia, Spain

Meca-Lallana, JE:
 Univ Lausanne, Lausanne Univ Hosp, Ctr Hosp Univ Vaudois, Lausanne, Switzerland

Martínez-Garcia, P:
 Univ Lausanne, Lausanne Univ Hosp, Ctr Hosp Univ Vaudois, Lausanne, Switzerland

Millán, J:
 Univ Lausanne, Lausanne Univ Hosp, Ctr Hosp Univ Vaudois, Lausanne, Switzerland

Bernard-Valnet, R:
 Hosp Gen Univ Elche, Dept Neurol, Alicante, Spain

González, I:
 Germans Trias & Pujol Hosp, Radiol Dept, Barcelona, Spain

García, AO:
 Hosp Univ Bellvitge, Dept Clin Sci,Hosp Univ Bellvitge, Inst Invest Biomed Bellvitge IDIBELL,Neurol & Neur, Sch Med,Multiple Sclerosis Unit,Dept Neurol,Neuros, LHospitalet De Llobregat, Barcelona, Spain

Tellez, R:
 Hosp Univ Bellvitge, Dept Clin Sci,Hosp Univ Bellvitge, Inst Invest Biomed Bellvitge IDIBELL,Neurol & Neur, Sch Med,Multiple Sclerosis Unit,Dept Neurol,Neuros, LHospitalet De Llobregat, Barcelona, Spain

Navarro, L:
 Hosp Reg Univ Malaga, Malaga, Spain

:
 Hosp Univ Clin San Cecilio, Serv Neurol, Granada, Spain

Romero-Pinel, L:
 Hosp Univ Girona Dr Josep Trueta, Hosp Santa Caterina, Unitat Neuroimmunol & Esclerosi Multiple Terr Giro, Girona 17190, Spain

Martínez-Yélamos, S:
 Hosp Univ Girona Dr Josep Trueta, Hosp Santa Caterina, Unitat Neuroimmunol & Esclerosi Multiple Terr Giro, Girona 17190, Spain

Cuello, JP:
 Hosp Civils Lyon, Hop Neurol Pierre Wertheimer, Neuropsychol Lab, Bron, France

Torres, AMA:
 Ctr Hosp Univ Bordeaux, Bordeaux, France

Piñar, R:
 CHU Hop Rouen, Rouen, France

Bravo, GA:
 Fdn Adolphe Rothschild Hosp, Paris, France

Benyahya, L:
 Hosp Civils Lyon, Hop Neurol Pierre Wertheimer, Serv Neurol, Sclerose Plaques Pathol Myeline & Neuroinflammat, Lyon, France

Trouillet-Assant, S:
 Montpellier Univ Hosp, Montpellier, France

Dyon-Tafani, V:
 Montpellier Univ Hosp, Montpellier, France

Tilikete, CF:
 Univ Autonoma Barcelona, Vall Hebron Hosp Univ, Vall Hebron Inst Recerca, Dept Radiol IDI,Sect Neuroradiol, Barcelona, Spain

Ruet, A:
 CHU Bordeaux, Serv Neurol, CHU CIC P0005, Inserm, Bordeaux, France

Bourre, B:
 CHU Rouen, Neurol, Rouen, France

Deschamps, R:
 Fdn Adolphe Rothschild Hosp, Paris, France

Papeix, C:
 Fdn Ophtalmol Adolphe Rothschild, Paris, Ile De France, France

Maillart, E:
 Fdn Ophtalmol Adolphe Rothschild, Paris, Ile De France, France

Kerschen, P:
 Ctr Hosp Luxembourg, Luxembourg Ville, Luxembourg, Luxembourg

Ayrignac, X:
 Montpellier Univ Hosp, Montpellier, France

Rovira, A:
 Univ Autonoma Barcelona, Vall Hebron Hosp Univ, Hosp Univ Vall Hebron,Sect Neuroradiol, Vall Hebron Inst Recerca,Dept Radiol IDI, Pg Vall dHebron 119-129, Barcelona 08035, Spain

Auger, C:
 Univ Autonoma Barcelona, Vall Hebron Hosp Univ, Hosp Univ Vall Hebron,Sect Neuroradiol, Vall Hebron Inst Recerca,Dept Radiol IDI, Pg Vall dHebron 119-129, Barcelona 08035, Spain

Audoin, B:
 Assistance Publ Hop Marseille, Marseille, France

Montalban, X:
 Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain

 Univ Autonoma Barcelona, Barcelona, Catalunya, Spain

Tintore, M:
 Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain

 Univ Autonoma Barcelona, Barcelona, Catalunya, Spain

Mariotto, S:
 Hosp Clin Univ Valladolid, Serv Neurol, Valladolid, Spain

Cobo-Calvo, A:
 Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain

 Univ Autonoma Barcelona, Barcelona, Catalunya, Spain
ISSN: 00223050





JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Editorial
BMJ Publishing Group, BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 96 Número: 9
Páginas: 884-892
WOS Id: 001421810500001
ID de PubMed: 39939136

MÉTRICAS